Abstract 336P
Background
For surgically resected breast cancer samples, it is challenging to perform specimen sampling by visual inspection, especially when the tumor bed shrinks after neoadjuvant therapy in breast cancer.
Methods
We developed a dual-mode near-infrared multispectral imaging system (DNMIS) to obtain richer sample tissue information by acquiring reflection and transmission images covering visible to NIR-II spectrum range (400–1700 nm). Additionally, artificial intelligence (AI) was used to segment the rich multispectral data. 80 breast cancer samples were collected to verify the advantage of DNMIS in assisting pathologists to identify tumor beds.
Results
DNMIS demonstrated better tissue contrast and eliminated the interference of surgical inks on the breast tissue surface, helping pathologists find the tumor area which is easy to be overlooked with visual inspection. Statistically, AI-powered DNMIS provided a higher tumor sensitivity (95.9% vs visual inspection 88.4% and X-rays 92.8%), especially for breast samples after neoadjuvant therapy (90.3% vs visual inspection 68.6% and X-rays 81.8%).
Conclusions
We infer that DNMIS can improve the breast tumor specimen sampling work by helping pathologists avoid missing out tumor foci.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
282P - Analysis of Prosigna in hormone receptor-positive early-stage breast cancer cohort after 8 years of experience at a single institution
Presenter: DANIEL MORCHÓN ARAUJO
Session: Poster session 02
283P - Patient profiles treated with extended adjuvant neratinib in the early access registry study: NEAR study
Presenter: Michelino De Laurentiis
Session: Poster session 02
284P - Prognostic and predictive impact of uPA/PAI-1 in early breast cancer
Presenter: Vanessa Wieder
Session: Poster session 02
285P - Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study
Presenter: Stefania Morganti
Session: Poster session 02
286P - Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study
Presenter: Antonino Musolino
Session: Poster session 02
287P - Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
Presenter: Johan Staaf
Session: Poster session 02
288P - Prognostic factors in nonmetastatic HER2 ‘low’ & HER2 ‘negative’ breast cancer: Single institute experience
Presenter: Alper Türkel
Session: Poster session 02
289P - Results of the window-of-opportunity clinical trial D-BIOMARK: Study of biomarkers of the antitumor activity of denosumab and its role as a modulator of the immune response in early breast cancer
Presenter: Andrea Vethencourt
Session: Poster session 02
290P - Metabolomic profiling and response to neoadjuvant therapy (NAT) in early breast cancer (EBC)
Presenter: Alessandra Gennari
Session: Poster session 02
291P - Prognostic implications of HER2 gain in patients with HR+/HER2- breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
Presenter: Emanuela Ferraro
Session: Poster session 02